异环磷酰胺联合长春瑞滨治疗晚期非小细胞肺癌疗效分析  

Ifosfamide and vinorelbine combined chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：劳逸[1] 陈绍锋[1] 雷桂华[1] 许德明[1] 王伟[1] 钟海鸣[1] 

机构地区：[1]广东省农垦中心医院肿瘤科,广东省湛江524002

出　　处：《中国基层医药》2006年第8期1302-1303,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的研究异环磷酰胺(IFO)联合长春瑞滨(NVB)的非铂类方案治疗非小细胞肺癌的疗效、毒性以找到一种临床上更有效方案。方法107例晚期非小细胞肺癌患者,采用IFO 1．5g/m^2静脉滴d1～d4,NVB 25mg/m^2静脉滴d1、d8,每3周重复,至少用2个周期。结果完全缓解3例．部分缓解48例,有效率47．7%；中位生存期10．3个月,1年生存率42%,2年生存率12．3%；主要的毒副反应为血液毒性,白细胞下降83．2%,其中Ⅲ～Ⅳ度37．4%；恶心呕吐24．3%。结论该方案是治疗晚期非小细胞肺癌较好的方案,毒副反应能耐受,是理想的值得临床首选的非铂类方案。Objective To evaluate therapeutic effects and toxicity of advanced non-small cell lung cancer （NSCLC,） treated by combining chemotherapy on ifosfamide（IFO） and vinorelbine（NVB）： Methods 107 cases patients with advanced NSCLC were enrolled. IFO was given in a dosage of 1.5g/m^2 on day 1 to 4. and NVB in a dosage of 25mg/m^2 on day 1 and 8. It was repeated every three or four weeks, up to two to four cycles. Results Two patients had complete response and 40 patients had partial response. The overall response rate was 47.7 % ,the median survival time 10.3 months, 1-year and 2-year survival rate was 42 % and 12.3 %, respectively. The main toxicity was bone marrow suppression. Conclusion The regimen is effective,sole and tolerable in advanced nonsmall cell lung cancer therapy.

关 键 词：异环磷酰胺 长春瑞滨 抗肿瘤联合化疗方案 癌 非小细胞肺 

分 类 号：R734.2[医药卫生—肿瘤]